Bidding 10-12 Aug 2026, price band ₹768–807, lot 18 shares.
GMP last updated: 17 Aug 2026, 8:53 AM IST
| Date | GMP (₹) | Est. Listing Price (₹) | Est. Listing Gain |
|---|---|---|---|
| 16 Aug | ₹116 | ₹923 | 14.37% |
| 15 Aug | ₹120 | ₹927 | 14.87% |
| 14 Aug | ₹125 | ₹932 | 15.49% |
| 13 Aug | ₹115 | ₹922 | 14.25% |
| 12 Aug | ₹156 | ₹963 | 19.33% |
| 11 Aug | ₹154 | ₹961 | 19.08% |
| 10 Aug | ₹138 | ₹945 | 17.10% |
| 9 Aug | ₹127 | ₹934 | 15.74% |
| 8 Aug | ₹132 | ₹939 | 16.36% |
| 7 Aug | ₹130 | ₹937 | 16.11% |
| 6 Aug | ₹180 | ₹987 | 22.30% |
| 5 Aug | ₹220 | ₹1,027 | 27.26% |
| 4 Aug | ₹170 | ₹977 | 21.07% |
| 3 Aug | ₹0 | ₹807 | 0.00% |
After allotment
Category-wise figures are not available right now.
Molbio Diagnostics is a point-of-care diagnostics company that develops and manufactures healthcare technologies for diagnosing infectious and non-communicable diseases. The company’s core business revolves around its proprietary ‘Truenat’ platform, a portable, battery-operated polymerase chain reaction (PCR) system designed for use in resource-limited settings. This platform provides rapid and accurate test results within approximately one hour. The company’s primary source of revenue is the sale of its ‘Truenat’ devices and the recurring sale of compatible, disease-specific micro-PCR test kits. Molbio offers a wide range of tests for various infectious diseases, including tuberculosis, COVID-19, Hepatitis B and C, HIV, and HPV. Through its subsidiaries, the company also provides devices related to radiology and digital pathology.